Investors
Welcome to OXB's Investors hub, your central resource for the latest company news, financial results, share information, and key updates. Here you’ll find everything you need to stay informed about our strategy, performance, and progress.
About OXB
OXB is a global contract development and manufacturing organisation (CDMO) at the forefront of cell and gene therapy. With 30 years of innovation and a deep track record in viral vector development, we partner with leading biopharma companies worldwide to accelerate the delivery of transformative medicines to patients.
As a listed company on the London Stock Exchange (LSE: OXB), we are focused on creating long-term value for our shareholders through strategic growth, operational excellence, and leadership in advanced therapies. Our mission-driven approach, combined with our scalable platform technologies and global network, positions OXB as a trusted partner and a compelling investment opportunity in one of the most dynamic areas of healthcare.
Regulatory news
Read OXB’s latest regulatory announcements, including results, trading updates, shareholder meetings, and other market disclosures – all in one place.
Results and investor materials
Access OXB’s financial results, annual reports, presentations, webcasts, and transcripts.
Corporate governance
Discover OXB’s governance framework, policies, and board committees that guide how the company creates long-term value.
Analyst coverage
The following table includes the names of sellside analysts that regularly publish research reports and recommendations on OXB.
Shareholder meetings, Circulars and Prospectuses
View major shareholders, shareholder meeting materials, including meeting notices, circulars, and prospectuses whenever you need them.
Investor events
Stay up to date with key milestones, from results announcements to capital markets days and industry events.
Investor contacts
Connect with us – find contact details for our Investor Relations team, registrars, and more.
2025 interim results
OXB has shared interim results for the six months ended 30 June 2025. The business has seen strong commercial progress, reiterating near-term and medium-term financial guidance.